Elutia recasts 2022 financials to reflect sale of Orthobiologics business as discontinued operations

ELUTIA INC.

Completed sale of Orthobiologics business to Berkeley Biologics LLC on November 8, 2023 for an undisclosed amount.
Asset Purchase Agreement with Berkeley dated September 17, 2023 triggered discontinued operations classification.
Historical results of Orthobiologics business reclassified as discontinued operations in recast 2022 Form 10-K.
Company now operates three segments: Device Protection, Women's Health, and Cardiovascular after sale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.